Gardasil Lawsuit 2026 Updates | Claims, Side Effects and Legal Status

The Gardasil vaccine lawsuits against Merck & Co. claim the company failed to provide complete information about HPV vaccine side effects. The cases involve multiple plaintiffs who developed autoimmune disorders, neurological problems and other permanent health issues after receiving their vaccinations.

The lawsuits focus on allegations that safety risks were not clearly communicated and that the vaccine’s safety profile was presented in a misleading way during testing and promotion. The lawsuits currently focus on new claims about medical transparency from the litigation, which raises questions about safety data and public risk communication.

What Is the Gardasil HPV Vaccine?

The vaccine Gardasil provides protection against multiple human papillomavirus (HPV) strains, which it was specifically designed to combat. The U.S. Food and Drug Administration approved the vaccine in 2006, and it has become a common tool for preventing HPV-related cancers, particularly cervical cancer. 

The vaccine helps the body develop immunity against high-risk HPV types before people come into contact with the virus. The vaccine works best when it is given to young children because it provides them with protection from disease early in their lives.

What Is Human Papillomavirus (HPV)?

Human Papillomavirus is a very common group of viruses that spreads through skin-to-skin contact. HPV has more than 200 different strains, and most people will not show any signs of infection. Most infections resolve themselves without the need for medical intervention.

The infection can produce warts through certain strains, while high-risk HPV develops into cancer after an extended period. These infections spread mainly through sexual intercourse.

Read about the Can You Sue Someone for Emotional Distress?

Who May Be Eligible to File a Gardasil Claim?

People may be considered for a Gardasil-related claim if they received the HPV vaccine and later developed serious health issues, especially when medical records support a possible connection. The evaluation focuses on three elements, which include medical diagnosis timing and available evidence. 

The following conditions are common in claims which people submit to health insurance providers – 

• Chronic fatigue, ongoing pain, or fibromyalgia
• Neurological issues, including brain fog or trouble focusing
• Sleep disturbances and severe headaches
• Nerve-related problems or damage
• Autoimmune conditions such as lupus
• Blood-related disorders like ITP
• Heart-related symptoms, including tachycardia or irregular heartbeat
• POTS (a condition affecting heart rate and blood flow)
• Reproductive health issues such as PCOS or menstrual irregularities
• Early menopause, ovarian failure, or primary ovarian insufficiency
• Digestive or gastrointestinal problems

Timelines on Gardasil Lawsuit Updates

The Gardasil HPV vaccine litigation has evolved through a series of key legal and procedural developments. From early case filings and discovery disputes to bellwether trial preparations and appellate rulings, the timeline captures how the multidistrict litigation has progressed and highlights critical moments that have shaped the course of these lawsuits. Here is an overview of the major events in the Gardasil lawsuit, illustrating the procedural milestones, court decisions, and ongoing developments.

July 4, 2025 – Appeal Initiated on Dismissed Gardasil Lawsuits

Over 100 Gardasil lawsuits alleging autoimmune disorders, including POTS and Primary Ovarian Insufficiency, have been appealed following dismissals by U.S. District Judge Kenneth Bell earlier this year. Plaintiffs contend that Judge Bell erred in ruling that federal preemption blocks their failure-to-warn claims, asserting that substantial evidence supports a causal link between the vaccine and serious injuries.

April 25, 2025 – Bellwether Plaintiffs File Appeal

Bellwether plaintiffs in the Gardasil MDL filed appeals to the Fourth Circuit after Judge Bell dismissed the majority of their claims. The plaintiffs are preparing their opening brief, which is scheduled for submission by May 27, 2025, aiming to challenge the dismissals and move their cases forward.

March 12, 2025 – Federal MDL Ruling Favors Merck

In the Western District of North Carolina, the MDL judge granted summary judgment for Merck, ruling that plaintiffs’ failure-to-warn claims regarding Gardasil and conditions like Postural Orthostatic Tachycardia Syndrome (POTS) and Primary Ovarian Insufficiency (POI) are preempted by federal law. The court concluded that Merck could not independently add such warnings without FDA approval, and since the FDA has never mandated them, state law claims conflict with federal regulations. This decision removes a central claim for plaintiffs in the federal MDL, marking a significant win for Merck.

The ruling applies only to federal MDL cases and does not affect state court litigation. Plaintiffs in state courts can still pursue claims under state law, including failure-to-warn, fraud, negligence, or design defect theories. Differences between state and federal litigation are evident, as seen in a Los Angeles trial involving a woman alleging a Gardasil-related heart condition. That case was postponed due to concerns about potential juror bias following Robert F. Kennedy Jr.’s confirmation as U.S. Secretary of Health and Human Services, given his past vaccine advocacy.

While federal plaintiffs face this preemption barrier, the broader Gardasil litigation continues in state courts. Federal MDL plaintiffs may now focus on alternative legal claims, but state-level lawsuits remain active, and the debate over Merck’s disclosure of Gardasil risks is ongoing.

Read about the OGX Lawsuits

March 8, 2025 – Gardasil and the Vaccine Court Dilemma

Although Gardasil falls under the National Vaccine Injury Compensation Program, it is not listed on the Vaccine Injury Table, which defines specific injuries presumed to be caused by certain vaccines within a set timeframe. Because of this, claimants cannot rely on a legal presumption of causation and must prove through medical records and expert testimony that Gardasil caused their injuries. Without table recognition, plaintiffs face a higher burden of proof, often requiring extensive scientific documentation and costly expert analysis to show that the vaccine more likely than not caused their condition.

February 19, 2025 – Los Angeles Trial Postponed

The first Gardasil safety trial was delayed due to concerns that media coverage of Robert F. Kennedy Jr.’s confirmation as Secretary of Health and Human Services might bias the jury. The case involved a plaintiff alleging the vaccine caused a severe heart condition, leaving her in a wheelchair. Merck denies any wrongdoing, maintaining that the vaccine’s risks were disclosed. The trial is now rescheduled for September with a new jury, highlighting the intersection of high-profile government appointments and ongoing litigation.

January 27, 2025 – First Gardasil Jury Trial

The initial jury trial in Gardasil litigation focused on claims that Merck misrepresented the HPV vaccine’s safety and efficacy. The plaintiff alleged she developed Postural Orthostatic Tachycardia Syndrome and nerve damage after vaccination. Merck defended itself, citing regulatory compliance, scientific evidence, and findings from the Vaccine Court and the CDC, which have not established a causal link between Gardasil and the claimed conditions.

January 20, 2025 – Trial Scheduled in California

The first Gardasil lawsuit in California is set to go to trial next week, marking a significant step in the state-level litigation. The case will examine allegations that the HPV vaccine caused serious health issues, and the outcome may influence other pending state court claims.

September 12, 2024 – Plaintiffs File Appeals After MDL Dismissals

Three women from the Gardasil multidistrict litigation announced plans to appeal to the Fourth Circuit following the dismissal of their cases for missing Vaccine Court deadlines. They sought equitable tolling, arguing that connecting their injuries to the vaccine was challenging, but the MDL judge denied their request.

September 3, 2024 – Slow Growth in MDL

The Gardasil MDL added only three new cases over the last two months, bringing the total number of pending cases to 200, indicating slow growth in federal filings.

August 4, 2024 – Four MDL Cases Dismissed

The MDL judge dismissed four claims due to procedural issues under the National Childhood Vaccine Injury Act. Three plaintiffs filed Vaccine Court petitions too late, and the fourth did not file at all or respond to motions to dismiss.

July 18, 2024 – State Court Trial Set

California state court litigation is moving faster than the MDL. The first trial, Robi v. Merck, is scheduled for October 7, 2024. The plaintiff alleges serious side effects, including heart complications and nerve pain, from receiving Gardasil.

July 1, 2024 – MDL Case Count Update

The Gardasil Products Liability Litigation in North Carolina saw a modest rise in active federal cases, increasing from 194 in June to 197 in July 2024.

June 12, 2024 – Bellwether Trial Date Expected Soon

Both parties in the Gardasil HPV vaccine MDL are nearing the completion of discovery for the initial bellwether cases. The MDL status conference scheduled for tomorrow is expected to set the date for the first trial. It appears likely that the initial Gardasil test case will proceed in California state court, involving a plaintiff who allegedly became permanently bedridden after receiving the vaccine.

June 3, 2024 – MDL Case Count Nears 200

The Gardasil class action MDL now includes 184 pending cases, up from approximately 140 three months ago. While the MDL is not experiencing rapid growth, the number of filings continues to increase steadily.

May 20, 2024 – Merck Files Motions to Dismiss

Merck requested dismissal of three Gardasil cases in the MDL, arguing that the plaintiffs failed to exhaust administrative remedies required under the National Vaccine Injury Act. The Act mandates that all vaccine-related claims must first be filed in Vaccine Court before civil litigation can proceed.

April 5, 2024 – New Case Study Highlights POTS Link

A recent case study from Utah documented a woman who developed postural orthostatic tachycardia syndrome, or POTS, shortly after receiving Gardasil in 2014. POTS is an autoimmune condition causing fainting, lightheadedness, and rapid heartbeat episodes. This case reinforces concerns about a potential connection between the vaccine and autoimmune or autonomic disorders.

March 29, 2024 – Judge Allows Gardasil MDL to Proceed

Merck’s motion to dismiss all Gardasil lawsuits based on the Vaccine Act was denied by MDL Judge Kenneth Bell. The judge ruled that claims regarding negligent failure to warn and fraudulent concealment of vaccine risks are not fully barred, allowing the litigation to continue and potentially paving the way for broader settlement discussions.

March 1, 2024 – 39 New Cases Added to MDL

The Gardasil class action MDL now has 143 pending cases, reflecting the addition of 39 new filings since the beginning of the year. This steady growth demonstrates continued interest from potential claimants seeking legal recourse related to Gardasil vaccine injuries.

January 9, 2024 – Status Conference in MDL

Judge Conrad convened a conference with attorneys to review the progress of the Gardasil MDL. The meeting focused on updates from both sides regarding discovery efforts, including access to Merck documents, questioning of company personnel, and coordination with related state court cases in California. The parties also discussed upcoming deadlines, including the completion of written discovery by February 15, general causation expert discovery by August 30, and the Daubert hearings scheduled for late January 2025. These hearings will be critical in determining the admissibility of expert testimony, a key factor in the litigation.

January 1, 2024 – MDL Adds 28 New Cases

In the first month of 2024, the Gardasil MDL grew by 28 cases, bringing the total pending cases to 132. This represents one of the highest monthly additions since the MDL began, signaling ongoing momentum in the litigation.

December 1, 2023 – Case Count Reaches 104 in MDL

By December, the Gardasil MDL had a total of 104 filed lawsuits, marking steady growth in the federal class action.

October 2, 2023 – MDL Status Hearing

A status hearing was held to provide the judge with updates on critical issues, including ongoing disputes over Merck’s document production, limits on discovery, and progress on the bellwether cases. The hearing highlighted the procedural and logistical challenges involved in managing a complex multidistrict litigation.

September 28, 2023 – Gardasil Lawyer Meeting

A status conference was held for the Gardasil class action, focusing on ongoing discovery disputes and updates regarding the bellwether cases that are being prepared for trial.

September 15, 2023 – Understanding Lexecon Waivers

Only Gardasil lawsuits selected as bellwether trial cases include a Lexecon waiver. This waiver allows cases normally assigned to other jurisdictions to be tried in North Carolina so that the MDL judge can oversee the trial, giving the court consistent control over bellwether proceedings.

September 1, 2023 – Preparing Bellwether Cases for Trial

Sixteen bellwether cases were chosen to undergo early test trials to help determine potential settlement values. By this status conference, 13 plaintiffs had amended complaints, and Merck had submitted case-specific responses. Depositions of plaintiffs’ parents are planned, as many received the vaccine at a young age. One case was dismissed and will be replaced to maintain the trial pool. The first trial is approaching, signaling an important stage in the litigation.

Read about the Average Payout for Ankle Injury With Surgery

August 28, 2023 – MDL Case Count Update

Since its creation in September 2022, the Gardasil MDL grew from 20 to 92 pending cases by late August 2023. Growth has slowed in recent months, with only 32 new cases added since the start of the year.

August 2, 2023 – Joint Status Report in MDL

A joint report submitted to the MDL judge highlighted ongoing developments. Plaintiffs are deposing corporate representatives of Merck under FRCP Rule 30(b)(6). Sixteen bellwether cases are currently in discovery, and plaintiffs continue to pursue adverse event data from Merck following an earlier motion to compel.

July 10, 2023 – Defendant Fact Sheets

Merck is required to submit a Defendant Fact Sheet (DFS) for each lawsuit after receiving the Plaintiff Fact Sheet (PFS). The DFS provides detailed case information and must be submitted within 45 days. Documents submitted in response are treated as formal evidence and remain confidential unless permission for sharing is granted.

June 27, 2023 – Bellwether Trial Preparation

The federal MDL judge and attorneys worked to outline steps leading to the first Gardasil trial. Sixteen potential bellwether cases have been identified. The outcome of the initial trial could significantly influence projected settlements—either raising compensation amounts or reducing them in case of dismissal.

June 1, 2023 – Bellwether Trial Plan

A bellwether program was established with 16 initial cases going through fact discovery. This pool will be narrowed to six cases eligible for the first trials next year. Plaintiffs will primarily involve patients experiencing Postural Orthostatic Tachycardia Syndrome (POTS) or Primary Ovarian Insufficiency (POI).

May 3, 2023 – Expert Reports Ruling

The court partially granted the plaintiffs’ motion to withhold expert reports filed in the Vaccine Court. Plaintiffs may withhold their consulting experts’ reports until deciding whether to retain them for the MDL, but must provide them to Merck within 10 days of a decision. Reports from DHHS experts must be produced within the same timeframe, as fairness rules do not apply.

April 14, 2023 – Document Discovery Ordered

In November 2022, plaintiffs in the Gardasil MDL requested that the court compel Merck to produce documents related to adverse event reports for Gardasil, claiming the company had withheld critical information. Merck opposed the motion, but the MDL judge ruled largely in favor of the plaintiffs. As a result, Merck is now required to provide all documents and data concerning its adverse event reporting system, along with other key records necessary for the litigation.

Read about the Depo-Provera Lawsuit Update

Real Case Examples From Gardasil Vaccine Lawsuits

Several lawsuits have been filed by individuals who claim they developed serious health issues after receiving the Gardasil. The legal cases demonstrate various types of reported injuries which developed over time.

1. Maesor Derr Case

The North Carolina case from 2022 involves a woman who got vaccinated at 13 years and later developed multiple health issues, including PCOS, autoimmune diseases and neurological disorders, which included POTS and dysautonomia.

2. Merrick Brunker Case

The 2022 case from California describes how the plaintiff began experiencing dizziness and fatigue right after receiving the vaccine. The patient experienced a decline, which progressed to severe headaches and numbness, thus requiring additional medical treatment.

3. Ashley Muller Case

The Florida lawsuit from 2021 states that the plaintiff developed POTS along with fatigue, joint pain, and brain fog after receiving multiple vaccine doses. The patient received additional diagnoses that included IBS and other medical complications.

4. Korrine Herlth Case

The 2021 Connecticut case investigates vaccine-related autoimmune disorders which emerged after vaccination. The vaccine protection level achieved through vaccination does not meet the required standard, according to the claim.

5. Zacharia Otto Case

The 2020 California case involves a young person who developed severe long-lasting health problems, which included POTS, fibromyalgia and nerve disorders. The symptoms reached a level which made it difficult to move and complete everyday activities.

Read about the Bard Hernia Mesh Settlement

Conclusion And What to Watch Next

The Gardasil lawsuits are still ongoing, with no final settlement or verdict yet. The key court decisions will determine how the claims will progress through the legal system because they will address scientific evidence, causation, and case processing methods. The rulings will determine which cases proceed to trial, which cases get dismissed and which cases result in settlements.

The outcome of the case will determine how vaccine safety risks will be communicated and monitored through future studies, which involve patients and their families and healthcare professionals. It could also affect how companies handle safety disclosures. The individuals who think they might have been affected need to stay updated about both legal progress and medical developments which occur during the process.

Read about the Ozempic Lawsuit Updates

FAQs — Common Questions About the Gardasil Cases